Leveron&Nexovas
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 2808  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 »   Next article
 »   Previous article
 »   Table of Contents

 Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2009    
    Printed75    
    Emailed1    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal

 

 
Year : 1995  |  Volume : 43  |  Issue : 2  |  Page : 77--82

Treatment of Parkinson's disease.


Department of Neurology, Sree Chitra Thirunal Institute of Medical Sciences & Technology, Thiruvanathapuram - 695011, India

Correspondence Address:
A Vijayaraghavan
Department of Neurology, Sree Chitra Thirunal Institute of Medical Sciences & Technology, Thiruvanathapuram - 695011
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 29542605

Rights and PermissionsRights and Permissions

Inspite of extensive research the ideal drug therapy for idiopathic Parkinson's disease (PD) and its optimal timing remain uncertain. Levodopa still is the mainstay of therapy for PD. Little evidence exists to incriminate early institution of levodopa therapy in the development of motor fluctuations and dyskinesias in PD. These complications are probably a consequence of disease progression, and resultant inability to synthesize and store dopamine, and buffer the variability in dopamine availability. Therefore, withholding levodopa therapy until late stage of the disease is not warranted. Dopa agonists provide only a short-term benefit. The neuroprotective effect of selegiline remains to be established. There is not enough evidence to justify the current practice of initiating treatment for PD patients with expensive polypharmacy. Research into the development of inexpensive levodopa containing preparations needs to be encouraged.






[PDF Not available]*


        
Print this article     Email this article

Online since 20th March '04
Published by Wolters Kluwer - Medknow